GlassScriptPhysician profile
Lynn Mason
NPI 1548447295
$2,257.45
in general payments reported to CMS, 2019-2025
32 companies · $424 in 2025
The $424 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $457 · 2022: $556 · 2023: $343 · 2024: $477 · 2025: $424.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,244.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,243.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $545.87 | 2021-2025 | |
| Mayne Pharma Commercial LLC | $277.04 | 2022-2025 | |
| Emd Serono, INC. | $156.91 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $138.02 | 2022-2025 | |
| Medtronic, INC. | $137.17 | 2024 | Abre |
| Eisai INC. | $131.58 | 2021 | |
| Hologic Sales and Service, LLC | $122.04 | 2024-2025 | Novasure, Myosure Tissue Removal Device, Aptima |
| Sumitomo Pharma America, INC. | $68.55 | 2023-2024 | Myfembree |
| Otsuka America Pharmaceutical, INC. | $58.02 | 2021-2022 | |
| Exact Sciences Corporation | $55.27 | 2023-2025 | Cologuard Collection Kit |
| Sunovion Pharmaceuticals INC. | $52.60 | 2021 | |
| Astellas Pharma US INC | $50.99 | 2023-2024 | Veozah |
| Tris Pharma INC | $50.58 | 2021-2022 | |
| Revance Therapeutics, INC. | $43.05 | 2025 | Daxxify |
| Janssen Pharmaceuticals, INC | $40.11 | 2021-2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exeltis, USA INC. | $28.46 | 2023-2025 | Slynd |
| Bausch Health US, LLC | $27.73 | 2022 | |
| Corium, LLC | $24.33 | 2022 | |
| Organon LLC | $23.96 | 2022 | |
| Alkermes, INC. | $23.69 | 2022 | |
| Ibsa Pharma INC. | $21.85 | 2024 | Licart, Tirosint |
| Allergan, INC. | $19.99 | 2021 | |
| Coopersurgical, INC. | $18.47 | 2024 | Paragard T 380a |
| Neurocrine Biosciences, INC. | $18.34 | 2021 | |
| Idorsia Pharmaceuticals US INC | $18.16 | 2023 | Quviviq |
| Lilly USA, LLC | $17.63 | 2025 | Zepbound |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $16.69 | 2022 | |
| Therapeuticsmd, INC. | $16.47 | 2022 | |
| Acella Pharmaceuticals, LLC | $14.92 | 2024 | NP Thyroid 60 |
| Merck Sharp & Dohme LLC | $14.66 | 2023 | Gardasil 9 |
| Alfasigma USA, INC. | $12.55 | 2021 | |
| Avanir Pharmaceuticals, INC. | $11.75 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lynn Mason listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.